Jazz Pharmaceuticals plc

NASDAQ:JAZZ  
157.25
+0.71 (+0.45%)
5:16:27 PM EDT: $157.00 -0.25 (-0.16%)
Positive Earnings Pre-Announcement

Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results And Raises Total Revenue Guidance Mid-Point

Published: 11/09/2022 21:43 GMT
Jazz Pharmaceuticals plc (JAZZ) - Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point.
Q3 Revenue Rose 12 Percent to $940.7 Million.
Raising the Mid-point of 2022 Total Revenue Guidance to $3.65 Billion.
Strong Operating Cash Flow Year-to-date of $930.0 Million, With a Cash Balance of $899.4 Million As of September 30, 2022.
Qtrly Loss per Share $0.31.
Qtrly Adjusted Earnings per Share 5.17.
Sees FY 2022 GAAP Net Income per Diluted Share $0.75 - $2.75.
Sees FY 2022 Non-GAAP Net Income per Diluted Share $17.20 - $17.857.
Q3 Earnings per Share View $4.66, Revenue View $939.1 Million -- Refinitiv Ibes Data (analyst estimates).
FY2022 Earnings per Share View $17.41, Revenue View $3.65 Billion -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $970.54 Million
Adjusted EPS is expected to be $4.42

Next Quarter Revenue Guidance is expected to be $852.94 Million
Next Quarter EPS Guidance is expected to be $4.25

More details on our Analysts Page.